Paroxetine

Paroxetine

Paroxetine Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Clinical Worsening and Suicide Risk:

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children,adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.

 Table 1
Age Range

Drug-Placebo Difference in Number of Cases of

Suicidality per 1,000 Patients Treated

 Increases Compared to Placebo
 <18 14 additional cases
 18-24 5 additional cases
Decreases Compared to Placebo
 25-64 1 fewer case
 ≥65 6 fewer cases

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONSand DOSAGE AND ADMINISTRATION: Discontinuation of Treatment With Paroxetine), for a description of the risks of discontinuation of paroxetine).

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for paroxetine tablets should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

Screening Patients for Bipolar Disorder

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that paroxetine tablets are not approved for use in treating bipolar depression

Serotonin Syndrome

The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including paroxetine, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of paroxetine with MAOIs intended to treat psychiatric disorders is contraindicated. Paroxetine should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking paroxetine. Paroxetine should be discontinued before initiating treatment with the MAOI (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).

If concomitant use of paroxetine with certain other serotonergic drugs, i.e., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, be aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

Treatment with paroxetine and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.

Angle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including paroxetine may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.

Potential Interation with Thioridazine:

Thioridazine administration alone produces prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsade de pointes-type arrhythmias, and sudden death. This effect appears to be dose related.

An in vivo study suggests that drugs which inhibit CYP2D6, such as paroxetine, will elevate plasma levels of thioridazine. Therefore, it is recommended that paroxetine not be used in combination with thioridazine (see CONTRAINDICATIONS and PRECAUTIONS).

Teratogenic Effects:

Epidemiological studies have shown that infants exposed to paroxetine in the first trimester of pregnancy have an increased risk of congenital malformations, particularly cardiovascular malformations. The findings from these studies are summarized below:

A study based on Swedish national registry data demonstrated that infants exposed to paroxetine during pregnancy (n = 815) had an increased risk of cardiovascular malformations (2% risk in paroxetine-exposed infants) compared to the entire registry population (1% risk), for an odds ratio (OR) of 1.8 (95% confidence interval 1.1 to 2.8). No increase in the risk of overall congenital malformations was seen in the paroxetine-exposed infants. The cardiac malformations in the paroxetine-exposed infants were primarily ventricular septal defects (VSDs) and atrial septal defects (ASDs). Septal defects range in severity from those that resolve spontaneously to those which require surgery.A separate retrospective cohort study from the United States (United Healthcare data) evaluated 5,956 infants of mothers dispensed antidepressants during the first trimester (n = 815 for paroxetine). This study showed a trend towards an increased risk for cardiovascular malformations for paroxetine (risk of 1.5%) compared to other antidepressants (risk of 1%), for an OR of 1.5 (95% confidence interval 0.8 to 2.9). Of the 12 paroxetine-exposed infants with cardiovascular malformations, 9 had VSDs. This study also suggested an increased risk of overall major congenital malformations including cardiovascular defects for paroxetine (4% risk) compared to other (2% risk) antidepressants (OR 1.8; 95% confidence interval 1.2 to 2.8).Two large case-control studies using separate databases, each with > 9,000 birth defect cases and > 4,000 controls, found that maternal use of paroxetine during the first trimester of pregnancy was associated with a 2- to 3-fold increased risk of right ventricular outflow tract obstructions. In one study the odds ratio was 2.5 (95% confidence interval, 1 to 6, 7 exposed infants) and in the other study the odds ratio was 3.3 (95% confidence interval, 1.3 to 8.8, 6 exposed infants).

Other studies have found varying results as to whether there was an increased risk of overall, cardiovascular, or specific congenital malformations. A meta-analysis of epidemiological data over a 16-year period (1992 to 2008) on first trimester paroxetine use in pregnancy and congenital malformations included the above-noted studies in addition to others (n = 17 studies that included overall malformations and n = 14 studies that included cardiovascular malformations; n = 20 distinct studies). While subject to limitations, this meta-analysis suggested an increased occurrence of cardiovascular malformations (prevalence odds ratio [POR] 1.5; 95% confidence interval 1.2 to 1.9) and overall malformations (POR 1.2; 95% confidence interval 1.1 to 1.4) with paroxetine use during the first trimester. It was not possible in this meta-analysis to determine the extent to which the observed prevalence of cardiovascular malformations might have contributed to that of overall malformations, nor was it possible to determine whether any specific types of cardiovascular malformations might have contributed to the observed prevalence of all cardiovascular malformations.

If a patient becomes pregnant while taking paroxetine, she should be advised of the potential harm to the fetus. Unless the benefits of paroxetine to the mother justify continuing treatment, consideration should be given to either discontinuing paroxetine therapy or switching to another antidepressant (see PRECAUTIONS: Discontinuation of Treatment With Paroxetine Tablets). For women who intend to become pregnant or are in their first trimester of pregnancy, paroxetine should only be initiated after consideration of the other available treatment options.

Animal Findings:

Reproduction studies were performed at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits administered during organogenesis. These doses are approximately 8 (rat) and 2 (rabbit) times the maximum recommended human dose (MRHD) on an mg/m2 basis. These studies have revealed no evidence of teratogenic effects. However, in rats, there was an increase in pup deaths during the first 4 days of lactation when dosing occurred during the last trimester of gestation and continued throughout lactation. This effect occurred at a dose of 1 mg/kg/day or approximately one-sixth of the MRHD on an mg/m2 basis. The no-effect dose for rat pup mortality was not determined. The cause of these deaths is not known.

Nonteratogenic Effects:

Neonates exposed to paroxetine tablets and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see WARNINGS— Serotonin Syndrome).

Infants exposed to SSRIs in pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1 – 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiologic studies suggest a positive statistical association between SSRI use (including paroxetine) in pregnancy and PPHN. Other studies do not show a significant statistical association.

Physicians should also note the results of a prospective longitudinal study of 201 pregnant women with a history of major depression, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission. Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their major depression compared to those women who remained on antidepressant medication throughout pregnancy.

When treating a pregnant woman with paroxetine, the physician should carefully consider both the potential risks of taking an SSRI, along with the established benefits of treating depression with an antidepressant. This decision can only be made on a case by case basis (see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS: Postmarketing Reports).

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Major Depressive Disorder:

Paroxetine tablets, USP are indicated for the treatment of major depressive disorder.The efficacy of paroxetine tablets, USP in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY —Clinical Trials). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.

The effects of paroxetine tablets, USP in hospitalized depressed patients have not been adequately studied.

The efficacy of paroxetine tablets, USP in maintaining a response in major depressive disorder for up to 1 year was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY —Clinical Trials). Nevertheless, the physician who elects to use paroxetine tablets, USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Obsessive Compulsive Disorder:

Paroxetine tablets, USP are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) as defined in the DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning.The efficacy of paroxetine tablets, USP were established in two 12-week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM-IIIR category of obsessive compulsive disorder (see CLINICAL PHARMACOLOGY —Clinical Trials).

Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable.

Long-term maintenance of efficacy was demonstrated in a 6-month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY — Clinical Trials). Nevertheless, the physician who elects to use paroxetine tablets, USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

Panic Disorder:

Paroxetine tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks.The efficacy of paroxetine tablets, USP were established in three 10- to 12-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY —Clinical Trials).

Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes.

Long-term maintenance of efficacy was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY —Clinical Trials). Nevertheless, the physician who prescribes paroxetine tablets, USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

History

There is currently no drug history available for this drug.

Other Information

Paroxetine tablets, USP are an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'-fluorophenyl)-3S-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the molecular formula of C19H20FNO3•HCl•1/2H2O. The molecular weight is 374.8 (329.4 as free base). The structural formula of paroxetine hydrochloride hemihydrate is:

chemical structure

Paroxetine hydrochloride, USP is an odorless, white to off-white crystalline powder, having a melting point range of 120° to 138°C. It is freely soluble in methanol, soluble in ethanol, sparingly soluble in dichloromethane and slightly soluble in water.

Each paroxetine tablet, USP intended for oral administration contains paroxetine hydrochloride hemihydrate equivalent to 10 mg or 20 mg or 30 mg or 40 mg of paroxetine. In addition, each tablet contains the following inactive ingredients: dibasic calcium phosphate anhydrous, hypromellose 6 cP, lactose anhydrous, magnesium stearate, polyethylene glycol 6000, povidone, sodium starch glycolate, talc, and titanium dioxide.

Paroxetine Manufacturers


  • St. Mary’s Medical Park Pharmacy
    Paroxetine Tablet, Film Coated [St. Mary’s Medical Park Pharmacy]
  • Cardinal Health
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Cardinal Health]
  • Proficient Rx Lp
    Paroxetine Tablet, Film Coated [Proficient Rx Lp]
  • Remedyrepack Inc.
    Paroxetine Tablet, Film Coated [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Remedyrepack Inc. ]
  • Blenheim Pharmacal, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Blenheim Pharmacal, Inc.]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Remedyrepack Inc. ]
  • State Of Florida Doh Central Pharmacy
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [State Of Florida Doh Central Pharmacy]
  • Gen-source Rx
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Gen-source Rx]
  • Solco Healthcare Us, Llc
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Solco Healthcare Us, Llc]
  • Alphapharm Pty. Ltd.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Alphapharm Pty. Ltd.]
  • Caraco Pharmaceutical Laboratories, Ltd.
    Paroxetine Tablet [Caraco Pharmaceutical Laboratories, Ltd.]
  • State Of Florida Doh Central Pharmacy
    Paroxetine (Paroxetine Hydrochloride) Tablet [State Of Florida Doh Central Pharmacy]
  • State Of Florida Doh Central Pharmacy
    Paroxetine (Paroxetine Hydrochloride) Tablet [State Of Florida Doh Central Pharmacy]
  • Major Pharmaceuticals
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Major Pharmaceuticals]
  • State Of Florida Doh Central Pharmacy
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [State Of Florida Doh Central Pharmacy]
  • Contract Pharmacy Services-pa
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Contract Pharmacy Services-pa]
  • Rebel Distributors Corp
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Rebel Distributors Corp]
  • Remedyrepack Inc.
    Paroxetine Tablet [Remedyrepack Inc. ]
  • Bryant Ranch Prepack
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Bryant Ranch Prepack]
  • Bryant Ranch Prepack
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Bryant Ranch Prepack]
  • Cardinal Health
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Cardinal Health]
  • Pd-rx Pharmaceuticals, Inc.
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • H.j. Harkins Company, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [H.j. Harkins Company, Inc.]
  • Pd-rx Pharmaceuticals, Inc.
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Cadila Healthcare Limited
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Cadila Healthcare Limited]
  • Pd-rx Pharmaceuticals, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Mckesson Contract Packaging
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Mckesson Contract Packaging]
  • Stat Rx Usa Llc
    Paroxetine Tablet, Film Coated [Stat Rx Usa Llc]
  • Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc]
  • Physicians Total Care, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Physicians Total Care, Inc.]
  • Mylan Institutional Inc.
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Mylan Institutional Inc.]
  • Stat Rx Usa Llc
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Stat Rx Usa Llc]
  • Bryant Ranch Prepack
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Bryant Ranch Prepack]
  • Preferred Pharmaceuticals, Inc.
    Paroxetine Tablet, Film Coated [Preferred Pharmaceuticals, Inc.]
  • Unit Dose Services
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Unit Dose Services]
  • Preferred Pharmaceuticals, Inc
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Preferred Pharmaceuticals, Inc]
  • Lake Erie Medical Dba Quality Care Products Llc
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Lake Erie Medical Dba Quality Care Products Llc]
  • Pd-rx Pharmaceuticals, Inc.
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Preferred Pharmaceuticals, Inc
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Preferred Pharmaceuticals, Inc]
  • Cardinal Health
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Cardinal Health]
  • Preferred Pharmaceuticals, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Preferred Pharmaceuticals, Inc.]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Paroxetine Tablet, Film Coated [Remedyrepack Inc. ]
  • Medvantx, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Medvantx, Inc.]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Remedyrepack Inc. ]
  • Lake Erie Medical Dba Quality Care Products Llc
    Paroxetine Tablet, Film Coated [Lake Erie Medical Dba Quality Care Products Llc]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Remedyrepack Inc. ]
  • Golden State Medical Supply, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Golden State Medical Supply, Inc.]
  • Major Pharmaceuticals
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Major Pharmaceuticals]
  • Remedyrepack Inc.
    Paroxetine Tablet, Film Coated [Remedyrepack Inc. ]
  • Ncs Healthcare Of Ky, Inc Dba Vangard Labs
    Paroxetine Tablet, Film Coated [Ncs Healthcare Of Ky, Inc Dba Vangard Labs]
  • Mylan Pharmaceuticals Inc.
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Mylan Pharmaceuticals Inc.]
  • Aidarex Pharmaceuticals Llc
    Paroxetine Tablet, Film Coated [Aidarex Pharmaceuticals Llc]
  • American Health Packaging
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [American Health Packaging]
  • Greenstone Llc
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Greenstone Llc]
  • Remedyrepack Inc.
    Paroxetine Tablet, Film Coated [Remedyrepack Inc. ]
  • International Labs, Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet [International Labs, Inc.]
  • Remedyrepack Inc.
    Paroxetine Tablet, Film Coated [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Remedyrepack Inc. ]
  • State Of Florida Doh Central Pharmacy
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [State Of Florida Doh Central Pharmacy]
  • Direct Rx
    Paroxetine Tablet, Film Coated [Direct Rx]
  • Cardinal Health
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Cardinal Health]
  • Aphena Pharma Solutions – Tennessee, Llc
    Paroxetine (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [Aphena Pharma Solutions – Tennessee, Llc]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Remedyrepack Inc. ]
  • Clinical Solutions Wholesale
    Paroxetine Tablet, Film Coated [Clinical Solutions Wholesale]
  • Aurobindo Pharma Limited
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Aurobindo Pharma Limited]
  • Cardinal Health
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Cardinal Health]
  • Cardinal Health
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Cardinal Health]
  • Bryant Ranch Prepack
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Bryant Ranch Prepack]
  • Zydus Pharmaceuticals (Usa) Inc.
    Paroxetine Tablet, Film Coated [Zydus Pharmaceuticals (Usa) Inc.]
  • Teva Pharmaceuticals Usa Inc
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Teva Pharmaceuticals Usa Inc]
  • Apotex Corp.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Apotex Corp.]
  • Aurolife Pharma Llc
    Paroxetine Tablet, Film Coated [Aurolife Pharma Llc]
  • Tya Pharmaceuticals
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Tya Pharmaceuticals]
  • Remedyrepack Inc.
    Paroxetine (Paroxetine Hydrochloride) Tablet, Film Coated [Remedyrepack Inc. ]
  • Proficient Rx Lp
    Paroxetine Tablet, Film Coated [Proficient Rx Lp]
  • Directrx
    Paroxetine Tablet, Film Coated [Directrx]

Login To Your Free Account